<DOC>
	<DOCNO>NCT02089451</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare pharmacokinetic property ( exposure trial drug body ) faster-acting insulin aspart ( FIAsp ) different injection region rout administration healthy subject .</brief_summary>
	<brief_title>A Trial Comparing Pharmacokinetic Properties Faster-acting Insulin Aspart ( FIAsp ) After Different Injection Regions Routes Administration Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Male female , age 1864 year inclusive time signing inform consent Considered generally healthy upon completion medical history , physical examination , analysis laboratory safety variable , vital sign ECG ( electrocardiogram ) , judge investigator Body mass index 20.028.0 kg/m^2 ( inclusive ) Subject donate blood plasma past month 500 mL within 3 month prior screen Smoker ( define subject smoking least one cigarette , cigar pipe daily ) Not able willing refrain smoking use nicotine substitute product inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>